These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26992707)

  • 21. Different antidiabetic regimens and the development of renal dysfunction in US Veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Wan J; Mangold TA; Wall BM
    J Investig Med; 2012 Oct; 60(7):1009-14. PubMed ID: 22801248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 23. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
    Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
    Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the role of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus.
    Graham JP; Stam D
    Pharm Pract Manag Q; 1997 Oct; 17(3):1-9. PubMed ID: 10173306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin regimens in type 2 diabetes.
    Cordido F
    N Engl J Med; 2010 Mar; 362(10):960; author reply 960. PubMed ID: 20225351
    [No Abstract]   [Full Text] [Related]  

  • 27. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
    Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
    Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical inquiries. What is the role of combination therapy (insulin plus oral medication) in type 2 diabetes?
    Eskesen S; Kelsberg G; Hitchcock K; Lo V
    J Fam Pract; 2006 Nov; 55(11):1001-3. PubMed ID: 17090364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T
    Coll Antropol; 2003 Jun; 27(1):181-7. PubMed ID: 12974145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients.
    Klein W
    Diabete Metab; 1991 May; 17(1 Pt 2):235-40. PubMed ID: 1936483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PURLs: Need an add-on to metformin? Consider this.
    Wyncott D; Lyon C; Mounsey A
    J Fam Pract; 2017 Jan; 66(1):42-44. PubMed ID: 28188318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfonylureas as second line treatment for type 2 diabetes.
    McGowan LD; Roumie CL
    BMJ; 2018 Jul; 362():k3041. PubMed ID: 30021790
    [No Abstract]   [Full Text] [Related]  

  • 35. Capsule Commentary on Pilla et al., Predictors of Insulin Initiation in Patients with Type 2 Diabetes: an Analysis of the Look AHEAD Randomized Trial.
    Chakkalakal RJ
    J Gen Intern Med; 2018 Jun; 33(6):944. PubMed ID: 29470817
    [No Abstract]   [Full Text] [Related]  

  • 36. Is There Enhanced Risk of Cerebral Ischemic Stroke by Sulfonylureas in Type 2 Diabetes?
    Parkinson FE; Hatch GM
    Diabetes; 2016 Sep; 65(9):2479-81. PubMed ID: 27555575
    [No Abstract]   [Full Text] [Related]  

  • 37. Capsule Commentary on Axon et al., Differential Impact of Homelessness on Glycemic Control in Veterans with Type 2 Diabetes Mellitus.
    Crowley MJ
    J Gen Intern Med; 2016 Nov; 31(11):1357. PubMed ID: 27503433
    [No Abstract]   [Full Text] [Related]  

  • 38. [Inappropriate use of sulfonylureas in older adults].
    Pacheco J
    Rev Med Chil; 2016 Nov; 144(11):1497. PubMed ID: 28394970
    [No Abstract]   [Full Text] [Related]  

  • 39. [Reply. Inappropriate use of sulfonylureas in older adults].
    Passi Á
    Rev Med Chil; 2016 Nov; 144(11):1497-1498. PubMed ID: 28394971
    [No Abstract]   [Full Text] [Related]  

  • 40. Erratum: Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin.
    Santeusanio AD; Bowen MM
    Diabetes Spectr; 2018 Nov; 31(4):367. PubMed ID: 30510394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.